(called service providers) trust the authentication token and map user roles accordingly.

Example: When a CRA logs into the central IdP, their access to eTMF, EDC, and CTMS is automatically authenticated and governed by a shared role schema.

Case Study: Federated Access in a Global Oncology Trial

A global Phase III oncology trial involving 40 sites across 10 countries implemented federated identity using SAML-based SSO.

• 💡 Users were issued unique tokens by the sponsor IdP
• 🧩 Each system (Medidata Rave, Veeva eTMF, IMP IRT) accepted the federated token
• 📊 Dashboards tracked user access in real time from a single point
• 📁 Deactivated users were removed from all systems in one step

Audit preparation time reduced by 45% and compliance errors related to access were cut by 60%.

Blockchain and Federated Identity: A Powerful Duo

When federated identity systems are layered with blockchain technology, the result is a highly auditable and tamper-resistant identity lifecycle:

• ⛓️ Immutable access logs for every login, logout, and system interaction
• 📅 Role assignments time-stamped on-chain
• 📜 Smart contracts that auto-revoke access based on contract expiration, role reassignment, or offboarding triggers

For example, a clinical research associate (CRA) assigned to a study site could have a smart contract enforcing automatic removal of system access 7 days after the last patient visit. This reduces dependency on manual SOP enforcement.

Learn more about blockchain-enhanced identity systems at PharmaValidation.in.

SOP and Validation Essentials for Federated Identity

To implement FIM in a GxP-compliant setting, documented SOPs and thorough validation are mandatory. These must include:

• 📖 SOP for identity provisioning and deprovisioning
• 🔍 Role-mapping matrix across systems
• 🔐 Audit procedure for access log review
• 📁 Backup and contingency plans if IdP fails

A validation approach would typically cover:

• IQ: Configuration of IdP, SP connectors, and user role mapping
• OQ: Authentication flow, login success/failure scenarios
• PQ: Real-world simulations of user access transitions, account lockouts, and revocations

Regulatory Audit Example: Identity Mapping Lapses

In a 2023 EMA inspection of a CRO-led vaccine study, an observation was issued for incomplete role mapping in their federated access setup. A blinded statistician had temporary unblinded access due to:

• 🧩 Mismatch in IdP vs SP role privileges
• 🕵️ Lack of final review after personnel change
• 🗃️ Failure to validate downstream system interpretation of federated tokens

CAPA measures included:

• Implementing test cases for role reassignment
• Creating blockchain-verified role transitions
• Updating SOP to require quarterly access role audit

More details on federated compliance can be found in ICH E6(R3) guidelines.

Best Practices for Implementing Federated Identity

• ✅ Always maintain a central user registry with unique trial identifiers
• ✅ Review and approve every SP-IdP connection via QA
• ✅ Avoid hardcoded role assignments; use dynamic role provisioning
• ✅ Encrypt federated tokens to prevent replay attacks
• ✅ Integrate federated access with eTMF filing of deactivation logs

For federated SOP templates, refer to PharmaSOP.in.

Conclusion: Identity Federation Enables Future-Ready Trials

Federated identity simplifies access control in increasingly complex, decentralized clinical trials. By combining SSO, central role governance, blockchain-enhanced traceability, and robust SOPs, trial sponsors and CROs can reduce errors, accelerate onboarding/offboarding, and ensure data integrity.

Identity federation is no longer optional—it’s foundational to secure, compliant, and scalable global trials.